Profil bibliographique

Ronald D’Amico

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

102Publications signalées

2591Citations signalées

2Affiliations récentes

Institutions déclarées

ViiV Healthcare (Spain)Hospital Universitario Príncipe de Asturias

Domaines associés

HIV/AIDS drug development and treatmentHIV Research and TreatmentHIV/AIDS Research and InterventionsHIV-related health complications and treatmentsImmune Response and Inflammation

Publications récentes

Accès ouvert 2025 articleOpenAlex

Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study

Eisuke Adachi, Yoshiyuki Yokomaku, Dai Watanabe, Hiroyuki Gatanaga et autres

0 citationsJournal of Infection and Chemotherapy

Accès ouvert 2025 articleOpenAlex

Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1

Ronald D’Amico, Kelong Han, Sherene Min, Rebecca DeMoor et autres

2 citationsAIDS

Accès ouvert 2025 articleOpenAlex

The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans

Rosie Mngqibisa, Yogita Singh, Catherine Orrell, Johan Lombaard et autres

2 citationsSouthern African Journal of HIV Medicine

Accès ouvert 2025 articleOpenAlex

Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357

Babafemi Taiwo, Yu Zheng, Katherine Rodríguez, Leah Burke et autres

5 citationsClinical Infectious Diseases

Accès ouvert 2025 articleOpenAlex

Strategies to Manage Dosing Deviations and Interruptions of Cabotegravir Long‐Acting Intramuscular Injections

Kelong Han, Ronald D’Amico, William Spreen, Susan L. Ford

0 citationsClinical Pharmacology in Drug Development

Accès ouvert 2025 articleOpenAlex

Cabotegravir pharmacokinetics in Asians with and without HIV

Kelong Han, Ahmed A. Abulfathi, Rashmi Mehta, Romina A. Nand et autres

0 citationsInternational Journal of Clinical Pharmacology and Therapeutics

Accès ouvert 2025 articleOpenAlex

Efficacy and safety of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in Japanese participants: 12-month results from the phase 3b randomized SOLAR trial

Eisuke Adachi, Yoshiyuki Yokomaku, Dai Watanabe, Hiroyuki Gatanaga et autres

1 citationJournal of Infection and Chemotherapy

Accès ouvert 2025 articleOpenAlex

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

Kelong Han, Paul Benn, Jörg Sievers, David Dorey et autres

6 citationsClinical Pharmacology in Drug Development

Accès ouvert 2025 articleOpenAlex

Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study

Susan L. Ford, Franco Felizarta, Kelong Han, Kehui Wang et autres

6 citationsClinical Infectious Diseases

2025 articleOpenAlex

Percutaneous Cholecystostomy as a Treatment for Acute Cholecystitis in Elderly Patients with High Surgical Risk

Rubén Jiménez‐Martín, Ronald D’Amico, Ruth Marcos-Hernández, Enrique Ovejero‐Merino et autres

0 citationsHPB

Accès ouvert 2024 articleOpenAlex

Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide

Darrell H. S. Tan, Andrea Antinori, Beng Eu, María José Galindo Puerto et autres

12 citationsJAIDS Journal of Acquired Immune Deficiency Syndromes

Accès ouvert 2024 articleOpenAlex

Population pharmacokinetics of cabotegravir following intramuscular thigh injections in adults with and without HIV

Kelong Han, Ronald D’Amico, William Spreen, Susan L. Ford

8 citationsAntimicrobial Agents and Chemotherapy

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.